Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT05256225 2026-04-16

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Phase 3 Recruiting

360 enrolled

Gynecologic

Neoplasms, Endometrial Neoplasms

NCT03914612 2026-04-13

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Phase 3 Active not recruiting

813 enrolled 16 charts 2 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT07198074 2026-04-13

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Phase 3 Recruiting

255 enrolled

Gynecologic

Endometrial Neoplasms

NCT06989112 2026-04-08

DE-01

Phase 3 Recruiting

600 enrolled

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Neoplasms, Endometrial Neoplasms

NCT03884101 2026-02-02

LEAP-001

Phase 3 Completed

842 enrolled 25 charts

Gynecologic

Endometrial Neoplasms

NCT04269200 2025-12-23

DUO-E

Phase 3 Active not recruiting

805 enrolled 18 charts 2 FDA

Gynecologic

Endometrial Neoplasms

NCT04865289 2025-12-02

LEAP-001

Phase 3 Completed

130 enrolled 24 charts

Gynecologic

Endometrial Neoplasms

NCT04634877 2025-06-09

KEYNOTE-B21

Phase 3 Active not recruiting

990 enrolled

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT03603184 2025-05-09

AtTEnd

Phase 3 Completed

549 enrolled

Gynecologic

Neoplasms, Endometrial Neoplasms

NCT05173987 2024-11-21

KEYNOTE-C93

Phase 3 Active not recruiting

280 enrolled

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT01820858 2024-04-02

EC-01

Phase 3 Active not recruiting

300 enrolled

Gynecologic

Endometrial Neoplasms

NCT02584478 2023-11-08

AL3818

Phase 3 Unknown

294 enrolled

Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT00411138 2023-10-11

PORTEC-3

Phase 3 Unknown

670 enrolled

Gynecologic

Endometrial Neoplasms

Clinical Trials

TroFuse-033

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

DE-01

LEAP-001

DUO-E

LEAP-001

KEYNOTE-B21

AtTEnd

KEYNOTE-C93

EC-01

AL3818

PORTEC-3